These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 8968695)

  • 1. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.
    Abraham R; Basser RL; Green MD
    Drug Saf; 1996 Dec; 15(6):406-29. PubMed ID: 8968695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
    Orditura M; De Vita F; Ciaramella F; Catalano G
    Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for prevention of anthracycline cardiotoxicity.
    Basser RL; Green MD
    Cancer Treat Rev; 1993 Jan; 19(1):57-77. PubMed ID: 8431927
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
    Sadurska E
    Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity.
    Hrdina R; Gersl V; Klimtová I; Simůnek T; Machácková J; Adamcová M
    Acta Medica (Hradec Kralove); 2000; 43(3):75-82. PubMed ID: 11089274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring for anthracycline cardiotoxicity.
    Lipshultz SE; Sanders SP; Goorin AM; Krischer JP; Sallan SE; Colan SD
    Pediatrics; 1994 Mar; 93(3):433-7. PubMed ID: 7818624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline associated cardiac toxicity in children with malignancies.
    Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
    Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
    Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
    Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
    Jain D
    J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
    Salvatorelli E; Menna P; Minotti G
    Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anthracycline cardiotoxicity].
    Finolezzi E; Torromeo C; Vincenzi B; Avvisati G
    Clin Ter; 2003; 154(2):115-21. PubMed ID: 12856371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.
    Chung R; Maulik A; Hamarneh A; Hochhauser D; Hausenloy DJ; Walker JM; Yellon DM
    Clin Cardiol; 2016 Feb; 39(2):72-82. PubMed ID: 26807534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.